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Abstract
Due to recent changes in federal and state legislations, the availability and
consumption of cannabis products have increased in the United States. The expanded use
of recreational and medicinal cannabis products increases the importance of
implementing sensitive and selective instrumental methods in toxicological laboratories,
as legal implications may arise in forensic cases, such as driving under the influence of
drugs (DUID). The purpose of this study was to perform a cross-validation for the
quantitative analysis of cannabinoids (Δ9-tetrahydrocannabinol, cannabidiol, cannabinol,
11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol) in
serum by gas chromatography coupled to triple quadrupole tandem mass spectrometry
(GCTQ). This method was fully validated following the Scientific Working Group for
Forensic Toxicology (SWGTOX) standard practices for method validation in forensic
toxicology. Linearity was established within 1-100 ng/ml; bias was within ± 20% and
imprecision was less than 20%; limits of detection (LOD) and quantitation (LOQ) were 1
ng/mL; and extraction efficiency ranged from 51.3 to 58.2%. Furthermore, the present
method and a previously developed method for the determination of cannabinoids in
blood were applied to serum (n = 20) and blood (n = 16) authentic case samples obtained
from the New York City Office of the Chief Medical Examiner (NYC-OCME) to
investigate a correlation between cannabinoid concentration in serum versus blood.
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Introduction
Cannabis, also known as marijuana, is a psychoactive substance that is obtained
from the Cannabis sativa plant (Levine, 2003; Negrusz & Cooper, 2013). Its main
psychoactive component is Δ9-tetrahydrocannabinol (THC); however, the plant contains
over 140 pharmacologically active cannabinoids, such as cannabidiol (CBD) and
cannabinol (CBN) (Levinsohn & Hill, 2020). In the human body, THC metabolizes into
11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC), which is the primary active
metabolite, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH), which is the
primary inactive metabolite (Levine, 2003).
Cannabis is the most commonly used illicit drug in the United States, with an
estimated 43.5 million Americans aged 12 or older having reported using marijuana in
2018 (Substance Abuse and Mental Health Services Administration, 2019). However,
cannabis also has been increasingly used therapeutically; it is estimated that more than
two million Americans utilize cannabis for therapeutic purposes (Levinsohn & Hill,
2020). In regard to its clinical application, cannabis has been used to treat a variety of
conditions, including multiple sclerosis, neuropathic pain, anxiety disorders, sleep
disorders, appetite stimulation for HIV/AIDS patients, and nausea and vomiting due to
chemotherapy (Citti, Braghiroli, Vandelli, & Cannazza, 2018). For example, Marinol®
(dronabinol, a synthetic form of THC) and Cesamet® (nabilone, a derivative of THC) are
medications that have been approved by the Food and Drug Administration (FDA) for the
treatment of nausea and vomiting due to chemotherapy (Levinsohn & Hill, 2020). In
addition, Epidiolex® is a medication containing CBD that has been approved by the FDA
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for the treatment of drug-resistant seizures that result from Dravet syndrome or LennoxGastaut syndrome (Kicman & King, 2014; Marcoux, Holmes, & Vogenberg, 2019).
Currently, thirty-three states and the District of Columbia have enacted laws
permitting the use of cannabis for medicinal purposes (Marcoux, Holmes, & Vogenberg,
2019; Peterman, 2019). Of these thirty-three states, eleven states and the District of
Columbia have legalized the use of cannabis for recreational purposes too (Levinsohn &
Hill, 2020). Despite its medicalization and legalization in several states, cannabis remains
classified as a Schedule I drug under the Controlled Substances Act because of its high
potential for abuse and absence of a currently accepted medical use in the US.
Nonetheless, the 2018 Farm Bill legalized the production of hemp containing less than
0.3% of THC (Marcoux, Holmes, & Vogenberg, 2019).
Cannabis is the most commonly detected illicit drug in driving under the influence
of drugs (DUID) cases (Compton, 2017; Hartman, Richman, Hayes, & Huestis, 2016).
Studies have concluded that cannabis impairs one’s driving ability due to its undesirable
effects on reaction time, cognitive performance, divided attention, perception, and
temporal and spatial orientation (Compton, 2017; Negrusz & Cooper, 2013). Specifically,
slight driving impairment has been observed at THC serum concentrations between 2-5
ng/mL, whereas significant driving impairment has been observed at THC serum
concentrations between 5-10 ng/mL (Urfer, Morton, Beall, Feldmann, & Gunesch, 2014).
Furthermore, cannabis use is associated with a significant dose-related decrease in
driving performance and an increased number of traffic crashes (Hartman et al., 2016;
Kicman & King, 2014; Negrusz & Cooper, 2013).
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All states have enacted laws that prohibit individuals from driving while impaired
by alcohol and/or other drugs (Compton, 2017). As of May 2019, eighteen states have
enacted per se laws that prohibit an individual from driving with a specified amount of
THC, which is commonly 5 ng/mL but ranges from 1-10 ng/mL in blood (Hartman et al.,
2016; Peterman, 2019). Other states have enacted zero tolerance laws that prohibit an
individual from driving with any measurable amount of THC or its metabolites in the
body (Compton, 2017). However, some studies have concluded that the concentration of
THC and its metabolites in blood may not be an accurate and reliable predictor of the
degree of impairment in an individual (Compton, 2017; Negrusz & Cooper, 2013;
Peterman, 2019).
The expanded use of recreational and medicinal cannabis products increases the
importance of implementing sensitive and selective instrumental methods in toxicological
laboratories, as legal implications may arise in DUID cases and other forensic cases.
Although blood tests are often performed for the determination of cannabinoids in DUID
cases, other biological matrices that are commonly examined include serum and plasma
(Citti et al., 2018; Compton, 2017; Peterman, 2019). Nonetheless, equivalence among
cannabinoid concentrations in blood, serum, and plasma has been scarcely explored
(Giroud et al., 2001; Raikos et al., 2014; Schaefer et al., 2015; Schwilke et al., 2009).
Solid phase extraction (SPE) or liquid-liquid extraction (LLE) followed by gas
chromatography (GC) coupled to different types of detectors, such as the flame ionization
detector (FID) and mass spectrometer (MS), has been traditionally employed for the
simultaneous determination of cannabinoids in biological specimens (Gasse, Pfeiffer,
Köhler, & Schürenkamp, 2016; Nahar, Guo, & Sarker, 2019; Purschke, Heinl, Lerch,
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Erdmann, & Veit, 2016; Schwilke et al., 2009). In addition, gas chromatography tandem
mass spectrometry (GC-MS/MS) methods using electron impact or chemical ionization
have been implemented to increase the sensitivity and specificity of the assay
(Andrenyak, Moody, Slawson, O’Leary, & Haney, 2017; Castro, Tarelho, Melo, &
Franco, 2018; Nahar et al., 2019). More recently, liquid chromatography mass
spectrometry (LC-MS) and liquid chromatography tandem mass spectrometry (LCMS/MS) methods using electrospray ionization have been reported because they do not
require derivatization (Citti et al., 2018; Gottardo, Sorio, Ballotari, & Tagliaro, 2019;
Lacroix & Saussereau, 2012; Raikos et al., 2014; Schaefer et al., 2015; Schwope,
Scheidweiler, & Huestis, 2011).
The purpose of this study was to perform a cross-validation for the quantitative
analysis of cannabinoids in serum by gas chromatography coupled to triple quadrupole
tandem mass spectrometry (GCTQ). Furthermore, the present method and a previously
developed method for the determination of cannabinoids in blood were applied to serum
(n = 20) and blood (n = 16) authentic case samples obtained from the New York City
Office of the Chief Medical Examiner (NYC-OCME) to investigate a correlation between
cannabinoid concentration in serum versus blood.

Materials and Methods
1. Reagents and Supplies
The certified reference materials for Δ9-tetrahydrocannabinol (THC, 1 mg/mL in
methanol), Δ9-tetrahydrocannabinol-d3 (THC-d3, 1 mg/mL in methanol), cannabidiol
(CBD, 1 mg/mL in methanol), cannabinol (CBN, 1 mg/mL in methanol), 11-hydroxy-Δ9-

5
tetrahydrocannabinol

(11-OH-THC,

1

mg/mL

in

methanol),

11-hydroxy-Δ9-

tetrahydrocannabinol-d3 (11-OH-THC-d3, 100 µg/mL in methanol), 11-nor-9-carboxyΔ9-tetrahydrocannabinol (THC-COOH, 1 mg/mL in methanol), and 11-nor-9-carboxyΔ9-tetrahydrocannabinol-d9 (THC-COOH-d9, 1 mg/mL in methanol) were purchased
from Cerilliant Corporation (Round Rock, TX, USA). HPLC-grade glacial acetic acid,
ethyl

acetate,

deionized

water

(diH2O),

ammonium

hydroxide,

and

N,O-

Bis(trimethylsilyl)trifluoroacetamide (with 1% trimethylchlorosilane) were purchased
from Thermo Fisher Scientific (Waltham, MA, USA). HPLC-grade hexane and LC/MSgrade acetonitrile were purchased from Spectrum Chemical (New Brunswick, NJ, US).
Blank (drug-free) calf blood was obtained from O. Ottomanelli & Sons (New
York, NY, US) for the preparation of the calibrator samples. Blank sheep serum was
purchased from Hemostat Laboratories (Dixon, CA, US) for the preparation of the quality
control (QC) samples. Hospital serum samples that previously screened negative for
cannabinoids by the enzyme-linked immunosorbent assay (ELISA) were obtained from
the NYC-OCME. Clean Screen Xcel II SPE columns were purchased from UCT, Inc.
(Bristol, PA, US) and placed on a SPEware CEREX® System 48 processor for positive
pressure SPE (Tecan, Männedorf, Switzerland). The eluent was evaporated under
nitrogen using a SPEware CEREX® 48 Concentrator (Tecan, Männedorf, Switzerland).

2. Instrumental Parameters
The analysis of cannabinoids in serum by GC-MS/MS was performed using an
Agilent 7890B GC System equipped with an autosampler and connected to an Agilent
7000C GC/MS Triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara,
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CA, US). Chromatographic separation was accomplished using an Agilent DB17MS
LTM column (15 m x 250 µm x 0.25 µm) and pre-column (1 m x 150 µm x 1.2 µm). The
temperature of the LTM column started at 200°C and increased to 250°C over 6.5 min,
remaining at 250°C for an additional minute of the run. Overall, the total run time was
9.5 min in which the GC system equilibrated back to initial conditions during the final
two minutes of the run.
The triple quadrupole mass spectrometer analyzed the compounds using electron
impact (EI) ionization mode. The data were collected using multiple reaction monitoring
(MRM) mode and processed using Agilent MassHunter Quantitative Analysis for QQQ.
The instrumental parameters for the five target analytes and three internal standards were
previously optimized by the Department of Forensic Toxicology at the NYC-OCME
(Table 1). 11-hydroxy-Δ9-tetrahydrocannabinol-d3 (11-OH-THC-d3) and 11-nor-9carboxy-Δ9-tetrahydrocannabinol-d9 (THC-COOH-d9) were employed as the deuterated
internal standards for 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9carboxy-Δ9-tetrahydrocannabinol (THC-COOH), respectively. Δ9-tetrahydrocannabinold3 (THC-d3) served as the internal standard for Δ9-tetrahydrocannabinol (THC),
cannabidiol (CBD), and cannabinol (CBN).
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Table 1. MRM GC-MS/MS parameters for the derivatized target analytes and internal
standards in serum (n = 8). The quantifier ion transitions are highlighted in bold.
Compound
Name

Retention
Time (min)

Precursor Ion
(m/z)

Product Ion
(m/z)

Collision
Energy (V)

CBD

4.2

390

301

15

375

15

319

15

303

20

330

10

289

25

310

40

323

35

295

45

289

20

305

15

265

15

371

289

15

488

297

20

488

371

20

389

306

20

330

10

292

25

292

20

308

15

268

15

380

292

15

497

306

20

497

380

20

THC

CBN

11-OH-THC

THC-COOH

THC-d3

11-OH-THC-d3

THC-COOH-d9

5

5.4

5.9

6.8

5

5.9

6.8

386

367

371

374
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3. Preparation of the Calibrator and QC Samples
The working stock solution containing the five cannabinoids was prepared at 10
mg/L in methanol. This solution was serially diluted to final concentrations of 0.1 and 1
mg/L for a total of three working stock solutions for the calibrator samples. This
procedure was repeated to create another set of working stock solutions for the QC
samples. The internal standard solution containing the three deuterated internal standards
was prepared at 0.5 mg/L in methanol. All these solutions were stored in a refrigerator at
5°C when not in use.

Table 2. Guidelines for the preparation of the calibrator and QC samples in 0.5 mL of
biological sample (blood or serum).
Sample Type

Final
Concentration
(ng/mL)

Working Stock
Solution (mg/L)

Volume Added
(µL)

Calibrator

1

0.1

5

5

0.1

25

10

0.1

50

25

1

12.5

50

1

25

80

1

40

100

1

50

3

0.1

15

20

1

10

70

1

35

QC

The mixed mode anion exchange SPE procedure required 0.5 mL of blank calf
blood or sheep serum to be aliquoted into labeled 16 x 125 mm glass culture tubes. The
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calibrator (1, 5, 10, 25, 50, 80, and 100 ng/mL) and QC (3, 20, and 70 ng/mL) samples
were prepared by spiking the appropriate working stock solution into 0.5 mL of blank
calf blood or sheep serum, respectively. The appropriate volumes of working stock
solution for the calibrator and QC samples are presented in Table 2.

4. Sample Extraction
The sample extraction procedure was based on the standard operating procedure
(SOP) for the analysis of cannabinoids in blood by GC-MS/MS at the NYC-OCME.
After fortifying the calibrator and QC samples with the appropriate volumes of working
stock solution, 25 µL of 0.5 mg/L internal standard solution was added to all the tubes for
a final concentration of 25 ng/mL. The samples were immediately vortexed using the
Scientific Industries Vortex Genie Z (Scientific Industries Inc., Bohemia, NY, USA).
Protein precipitation involved adding 1.5 mL of ice-cold acetonitrile to each sample
dropwise while vortexing, followed by centrifugation at 3,000 rpm for 10 min. The
acetonitrile was decanted into labeled 10 mL conical test tubes and evaporated under
nitrogen to approximately 200 µL. After vortexing the samples, 2 mL of diH2O was
added to all the tubes and the samples were vortexed again. The samples were decanted
onto UCT Clean Screen Xcel II solid phase extraction cartridges that were placed on a
positive pressure manifold, and passed through the column at 1-2 psi. Subsequently, the
columns were washed with 2 mL of diH2O: acetonitrile: ammonium hydroxide (84:15:1,
v/v) and dried for 10 min at 60 psi. The target analytes were eluted into labeled 16 x 125
mm glass culture tubes with 2 mL of hexane: ethyl acetate: glacial acetic acid (49:49:2,
v/v) by gravity, and evaporated to dryness under nitrogen at room temperature. Then, the

10
samples were reconstituted with 50 µL of ethyl acetate and derivatized with 50 µL of
BSTFA (with 1% TMCS). After capping and vortexing all the tubes, the samples were
incubated for 30 min at 70° C. Finally, the derivatized extracts were transferred to labeled
screw-capped vials with polymer feet inserts for GC-MS/MS analysis.

5. Method Cross-Validation
The cross-validation for the analysis of cannabinoids in serum by GC-MS/MS
was performed using the Scientific Working Group for Forensic Toxicology (SWGTOX)
standard practices for method validation in forensic toxicology (Scientific Working
Group for Forensic Toxicology, 2013). The reference methodology was the determination
of cannabinoids in whole blood by GC-MS/MS, which was previously developed and
validated at the NYC-OCME Forensic Toxicology Laboratory. The following parameters
were assessed: bias, imprecision, limit of detection (LOD), limit of quantitation (LOQ),
interferences, extraction efficiency, dilution integrity, and stability. The other validation
parameters of calibration model and carryover were previously evaluated during the
validation of cannabinoids in blood by GC-MS/MS at the NYC-OCME.

a. Bias and Imprecision
Bias and imprecision were concurrently evaluated by monitoring QC samples at
3, 20, and 70 ng/mL over a course of five extractions with different calibration curves (n
= 15). The maximum acceptable bias was not to exceed ± 20% at each QC concentration.
Similarly, the within-run and between-run precisions, which were calculated using the
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one-way analysis of variation (ANOVA) approach, were not to exceed 20% at each QC
concentration.

b. Limit of Detection (LOD) and Limit of Quantitation (LOQ)
The LOD and LOQ were designated as the value of the lowest non-zero calibrator
sample (1 ng/mL). Blank hospital serum samples from three different sources were
analyzed using the criteria for detection, identification, bias, and imprecision. In order to
meet the requirements for the LOD, the samples must produce a reproducible instrument
response that is greater than 3x the signal-to-noise ratio (S/N) of the blank sample. For
the LOQ, the samples must produce a reproducible instrument response that is greater
than 10x the S/N of the blank sample, and result in bias not exceeding ± 20% and
imprecision less than 20%.

c. Interferences
Endogenous interferences were studied by extracting blank serum samples from
ten different sources without the addition of internal standard solution. Interferences from
the reference standards were studied by fortifying blank serum samples with either the
target analytes at the upper limit of the calibration range (100 ng/mL) or the internal
standard solution, both in triplicate. Interferences from high concentrations of CBD were
investigated by extracting a 500 ng/mL sample of CBD and monitoring its possible
conversion into THC.

12
d. Extraction Efficiency
Extraction efficiency was evaluated by comparing the area responses of five QC
samples to ten blank serum extracts with post-extraction cannabinoid addition. Extraction
efficiency was evaluated at the low (3 ng/mL) and high (70 ng/mL) QC concentrations.

e. Dilution Integrity
Dilution integrity was investigated by performing 1:2 and 1:5 dilution ratios of a
150 ng/mL sample, both in triplicate, and evaluating their effects on bias.

f. Stability
The stability of the derivatized extracts was evaluated by re-injecting the low and
high QC samples on the autosampler after 24, 48, and 72 h at room temperature. The
percent differences between the initial and re-injected QC samples were calculated in
which the maximum acceptable percent difference was not to exceed ± 20% at each QC
concentration.

6. Identification and Quantification Criteria
The criteria that were used for the identification of target analytes consisted of the
following: the retention time must be within ± 2% of the average calibrator retention
time, one quantifier and two qualifier product ions must be present, and the ion ratio
qualifier/quantifier must be within ± 20% of the average calibrator ion ratios. In order to
quantify the target analytes, the calibration curve for each target analyte must have an r2
value greater than 0.99. However, the NYC-OCME permits the exclusion of up to two
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calibration points for a total of five calibration points to improve calibration curve
linearity, calibrator or QC accuracy, or account for spiking or extraction issues in a
specific calibrator sample.

7. Authentic Case Sample Analysis
The NYC-OCME Forensic Toxicology Laboratory provided serum (n = 20) and
blood (n = 16) authentic case samples for the analysis of cannabinoids by GC-MS/MS.
These samples were selected because they previously screened positive for cannabinoids
by ELISA during initial testing. In addition, these samples were submitted between
January and May of 2019, and stored in vacutainer glass collection tubes in a refrigerator
at 5°C when not in use. The blood sample sources included femoral (n = 1) and hospital
blood (n = 15). Among these serum and blood authentic case samples, there were eight
paired blood and serum samples that were collected at the same time at the hospital. The
manner of death for these paired blood and serum samples included three accidental
deaths, two homicides, and three natural deaths. Furthermore, these eight paired blood
and serum samples were used for the comparison of cannabinoid concentration in serum
versus blood.

Results
1. GC-MS/MS Method Cross-Validation in Serum
The analysis of cannabinoids in serum by GC-MS/MS demonstrated excellent
sensitivity and selectivity in which all the target analytes were detected and quantified
within the calibration range of 1-100 ng/mL (Figure 1).
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Figure 1. Total ion chromatogram (TIC) of a low QC (3 ng/mL) sample in sheep serum.
The five target analytes eluted in the following order: CBD, THC, CBN, 11-OH-THC,
and THC-COOH.

The cross-validation for cannabinoids in serum by GC-MS/MS was based on the
previous validation for cannabinoids in blood by GC-MS/MS at the NYC-OCME. These
methods were validated for the simultaneous quantification of five cannabinoids: THC,
CBD, CBN, 11-OH-THC, and THC-COOH. The results from the cross-validation for
cannabinoids in serum by GC-MS/MS are summarized in the following sections.

a. Bias and Imprecision
Bias and imprecision were concurrently evaluated by monitoring QC samples at
the low (3 ng/mL), mid (20 ng/mL), and high (70 ng/mL) QC concentrations. All the
target analytes showed acceptable bias (± 20%) and imprecision (< 20%), except for
THC-COOH. Although THC-COOH failed the bias criteria with a bias of -27.6% at the
mid QC concentration, it showed acceptable imprecision at each QC concentration. The
bias and imprecision results for the target analytes in serum are presented in Tables 3 and
4, respectively.
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Table 3. Summary of bias results at each QC concentration (3, 20, and 70 ng/mL) for the
target analytes in serum (n = 15).
Compound
Name

Bias (%)
Low QC

Mid QC

High QC

CBD

-17.1

-19.8

-18.1

THC

-7.9

-11.3

-11.3

CBN

-13.8

-14.9

-17.1

11-OH-THC

-8.5

-9.4

-8

THC-COOH

5.7

-27.6

7.4

Table 4. Summary of imprecision results at each QC concentration (3, 20, and 70 ng/mL)
for the target analytes in serum (n = 15).
Compound
Name

Low QC

Mid QC

High QC

Intra-day
%CV

Inter-day
%CV

Intra-day
%CV

Inter-day
%CV

Intra-day
%CV

Inter-day
%CV

CBD

9.6

5.5

9.6

6.1

10

6.4

THC

7.2

4

6.2

3.8

4.9

3.2

CBN

17.1

7.1

7.3

4

11.3

4.9

11-OH-THC

6.4

2.7

5.4

3.3

4.9

3.1

THC-COOH

12.4

5.3

14.4

7.9

6.9

3.1

b. Limit of Detection (LOD) and Limit of Quantitation (LOQ)
At the LOD and LOQ (1 ng/mL), the bias results were within ± 20% of the target
range (0.8-1.2 ng/mL) and the imprecision results were less than 20% for all the target
analytes (Table 5). In addition to satisfying the identification criteria, each target analyte
produced a reproducible instrument response that was greater than 10x the S/N of the
blank sample.

16
Table 5. Summary of bias and imprecision results at the LOD and LOQ (1 ng/mL) for
the target analytes in serum (n = 9).
Compound Name

Bias (%)

Imprecision (%CV)
Intra-day

Inter-day

CBD

-7.2

12

16.6

THC

-4.8

9.7

16.5

CBN

5.2

5.4

9.7

11-OH-THC

-11.4

3.3

9.7

THC-COOH

2.3

14.9

19.5

c. Interferences
The presence of exogenous interferences from high concentrations of CBD was
investigated by extracting a 500 ng/mL sample of CBD in triplicate. THC-COOH was
detected in two replicates at 0.3 and 0.4 ng/mL. Similarly, THC-COOH was detected in
all three replicates at concentrations ranging from 1.1-1.6 ng/mL during the validation of
cannabinoids in blood by GC-MS/MS.
No matrix interferences were observed from the serum matrices used (n = 10). In
addition, blank serum samples that were fortified with internal standard solution only did
not produce positive results for the target analytes. However, 11-OH-THC-d3 was
detected in two replicates of the blank serum samples that were fortified with the target
analytes at the upper limit of the calibration range (100 ng/mL). The response of 11-OHTHC-d3 was approximately 2-3.5% of its response when compared to samples that were
fortified with internal standard solution too. Similarly, 11-OH-THC-d3 was detected in all
three replicates during the validation of cannabinoids in blood by GC-MS/MS.
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d. Extraction Efficiency
Extraction efficiency was evaluated by comparing the area responses of five QC
samples to ten blank serum extracts with post-extraction cannabinoid addition. All the
target analytes demonstrated optimal extraction efficiencies (> 50%), ranging from 51.3%
for THC-COOH to 58.2% for CBN at the high QC (70 ng/mL) concentration (Table 6).
However, the SPE procedure, poor derivatization, and protein precipitation step could
have contributed to the reduced recovery of the target analytes.

Table 6. Summary of extraction efficiency results at the low (3 ng/mL) and high (70
ng/mL) QC concentrations for the target analytes in serum (n = 5).
Compound Name

Extraction Efficiency (%)
Low QC

High QC

CBD

53.9

56.5

THC

52.3

57.1

CBN

54.3

58.2

11-OH-THC

57.6

54.9

THC-COOH

57.5

51.3

e. Dilution Integrity
Dilution integrity was investigated by performing 1:2 and 1:5 dilution ratios of a
150 ng/mL sample, both in triplicate, and evaluating their effects on bias. When the
dilution factors of 2 and 5 were applied on Agilent MassHunter Quantitative Analysis for
QQQ, the average concentrations of CBD and CBN fell below the target range (120-180
ng/mL). In contrast, the average concentrations of THC, 11-OH-THC, and THC-COOH
calculated within the target range (Table 7).
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Table 7. Summary of dilution integrity results for the target analytes in serum (n = 3).
The concentrations should be within ± 20% of the target concentration (120-180 ng/mL).
Compound Name

Average Concentration (ng/mL)
1:2 Dilution Ratio

1:5 Dilution Ratio

CBD

88.1

89.9

THC

123.4

123.1

CBN

104.9

108.2

11-OH-THC

126.4

124.3

THC-COOH

140.8

136

f. Stability
The stability of the derivatized extracts was evaluated by comparing the percent
differences between the initial and re-injected low and high QC samples on the
autosampler after 24, 48, and 72 h at room temperature. All the target analytes had
percent differences less than 20%, except for THC. THC showed percent differences ≥ 21.4% at the high QC concentration (70 ng/mL) after 24 h on the autosampler and ≥ 20.9% at the low QC concentration (3 ng/mL) after 48 h on the autosampler. Therefore,
samples that are on the autosampler for at least 24 h are not expected to provide
consistent concentrations as compared to initial injections.

2. Comparison of Validation Parameters in Serum vs. Blood
All the validation parameters that were assessed during the cross-validation in
serum were previously evaluated during the validation in blood by GC-MS/MS. Overall,
the results were similar in both biological matrices. The following sections summarize
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the main differences between the results from the cross-validation in serum and
validation in blood by GC-MS/MS at the NYC-OCME.

a. Calibration Curve Linearity
The calibration models for the target analytes were previously established during
the validation of cannabinoids in blood by GC-MS/MS at the NYC-OCME. The
calibration models were evaluated within the range of 1-100 ng/mL by fortifying blank
calf blood samples with the appropriate volumes of working stock solution over a course
of five extractions. The calibration models that best fit the data by having the lowest
standard deviation of residuals are summarized in Table 8.

Table 8. Linearity parameters for the target analytes in blood (n = 5).
Compound
Name

Linear
Range
(ng/mL)

Weighting

Average
R2 Value

CV% of
R2 Values

Average
Slope

CV% of
Slopes

CBD

1-100

1/x2

0.9928

0.2

6.8162

11

THC

1-100

1/x

0.997

0.3

0.9564

5.7

CBN

1-100

1/x2

0.9962

0.2

31.428

5.8

11-OHTHC

1-100

1/x

0.9969

0.3

1.0137

5.9

THCCOOH

1-100

1/x2

0.9947

0.3

1.1674

6.1

b. Bias and Imprecision
As depicted in Table 3, THC-COOH failed the bias criteria with a bias of -27.6%
at the mid QC concentration (20 ng/mL) in serum. In contrast, all the target analytes
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showed acceptable bias during the validation of cannabinoids in blood. In addition, the
imprecision results for all the target analytes were similar in both biological matrices.

c. Limit of Detection (LOD) and Limit of Quantitation (LOQ)
At the LOD and LOQ (1 ng/mL), the bias results were within the target range
(0.8-1.2 ng/mL) and the imprecision results were less than 20% for all the target analytes
in serum. In addition, each target analyte produced a reproducible instrument response
that was greater than 10x the S/N of the blank sample. During the validation of
cannabinoids in blood, THC-COOH failed the bias criteria with a bias of 34.3% but
presented acceptable imprecision and S/N.

d. Extraction Efficiency
As depicted in Table 6, all the target analytes demonstrated extraction efficiencies
(> 50%) at the low (3 ng/mL) and high (70 ng/mL) QC concentrations in serum. All the
target analytes exhibited lower extraction efficiencies in blood, ranging from 22.8% for
THC-COOH at the high QC concentration (70 ng/mL) to 45.4% for CBD at the low QC
concentration (3 ng/mL). Although this validation parameter did not have specific pass or
fail criteria, the results suggest that this extraction procedure recovers the target analytes
more efficiently in serum than blood (Table 9).
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Table 9. Comparison of extraction efficiency results at the low (3 ng/mL) and high (70
ng/mL) QC concentrations for the target analytes in blood and serum (n = 5).
Compound
Name

Extraction Efficiency (%)
Blood

Serum

Low QC

High QC

Low QC

High QC

CBD

45.4

42.3

53.9

56.5

THC

36.2

35.3

52.3

57.1

CBN

33.9

35.1

54.3

58.2

11-OH-THC

35.2

32.9

57.6

54.9

THC-COOH

27.4

22.8

57.5

51.3

e. Dilution Integrity
The dilution integrity results suggest that sample dilution in blood provides more
accurate and reliable quantitative results for all the target analytes. In contrast to the
results presented in Table 7, the average concentrations for all the target analytes were
within the target range (120-180 ng/mL) during the validation of cannabinoids in blood.

f. Stability
The stability results indicate that the derivatized extracts were more stable in
blood than serum when left on the autosampler after given time intervals at room
temperature. During the validation of cannabinoids in blood, all the target analytes had
percent differences within ± 20%, except for CBN with a percent difference of 20.9% at
the low QC concentration (3 ng/mL) after 72 h on the autosampler.
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3. Authentic Case Sample Analysis
Overall, 20 serum samples and 16 blood samples were analyzed for cannabinoids
by GC-MS/MS. The most commonly detected target analyte was THC-COOH, which
was detected in all the serum and blood samples. THC and 11-OH-THC were detected in
one serum sample and six blood samples, CBD was detected in one blood sample, and
CBN was not detected in either biological matrix. Figures 2 and 3 illustrate the overall
trend of the target analytes being more frequently detected in blood than serum.

Figure 2. Total ion chromatogram (TIC) of serum sample from case number 7. THCCOOH (3.2 ng/mL) was detected.

Figure 3. Total ion chromatogram (TIC) of hospital blood sample from case number 7.
THC (1.8 ng/mL), 11-OH-THC (1.4 ng/mL), and THC-COOH (8.8 ng/mL) were
detected.
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Table 10 provides the range and median concentrations for the target analytes that
were detected in the serum (n = 20) and blood (n = 16) authentic case samples. Target
analytes that were detected at concentrations less than the LOD and LOQ (1 ng/mL) were
not included in these results.

Table 10. Summary of target analyte concentrations in blood (n = 16) and serum (n = 20)
authentic case samples.
Compound
Name

Statistics

CBD

Range

Blood (ng/mL)
Femoral
1.2

Median
THC

Hospital

Serum
(ng/mL)

# of Cases

1

Range

4.6

Median

-----

-----

1.8 – 7.7

2.5

2

# of Cases

1

5

1

CBN

-----

-----

-----

-----

11-OH-THC

Range

1.8

1.3 – 3.2

1.5

Median
THC-COOH

2.1

# of Cases

1

5

1

Range

>100

2.5 – >100

2 – >100

21.1

9

15

20

Median
# of Cases

1

Furthermore, the ratio of THC-COOH concentration in blood to serum was
calculated for each paired blood and serum authentic case (n = 8). The average blood-toserum ratio was 2.1, which indicates that THC-COOH was generally detected at higher
concentrations in blood than serum (Table 11). However, this ratio was less than 1 for
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three paired blood and serum authentic cases, which demonstrates that THC-COOH was
detected at higher concentrations in serum than blood too. As illustrated in Figure 4, no
strong correlation was observed between the different matrix concentrations for THCCOOH.

Table 11. Ratio of THC-COOH concentration in blood to serum from paired blood and
serum authentic cases (n = 8).
Statistics

Blood-to-Serum Ratio

Mean

2.1

Standard Deviation

1.8

Range

0.4 – 5.6

Figure 4. Scatter plot of THC-COOH concentration in serum versus blood from paired
blood and serum authentic cases (n = 8).
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Discussion
Compared to the methods that are currently published in the literature, the present
method requires a small volume of serum sample (0.5 mL) and encompasses a
comprehensive working range of 1-100 ng/mL for these five target analytes (Citti et al.,
2018; Gottardo et al., 2019). All the target analytes presented acceptable bias and
imprecision, except for THC-COOH at the mid QC concentration (20 ng/mL). This is not
considered a major concern for the quantification of THC-COOH because its bias results
were within ± 20% at the other QC concentrations, its precision results were less than
20%, and it did not affect the other validation parameters. Although some methods utilize
lower LOD and LOQ values, this is not critical because the cut-offs for initial and
confirmatory testing of cannabinoids in blood require analytical results as low as 1
ng/mL, which is the value of the LOD and LOQ for the present method.
The interferences that resulted from fortifying blank serum samples with either a
high concentration of CBD or the target analytes at the upper limit of the calibration
range (100 ng/mL) were also present during the validation of cannabinoids in blood by
GC-MS/MS, and are not expected to interfere with the assay. The dilution integrity
results suggest that sample dilution in blood provides more accurate and reliable
quantitative results for all the target analytes. In addition, the stability results suggest that
THC is unstable in serum when left on the autosampler at room temperature. In contrast,
studies have reported that THC remains stable in serum when left on the autosampler
after 24 h (Gasse et al., 2016; Purschke et al., 2016). Nonetheless, the stability results for
THC were very close to the maximum acceptable percent difference (± 20%). Perhaps,
refrigeration or rederivatization of the processed samples could improve the stability of
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THC (Andrenyak et al., 2017). Furthermore, all the target analytes demonstrated greater
extraction efficiencies in serum than blood.
Although THC-COOH was detected in all the serum and blood authentic case
samples, the other target analytes were more commonly detected in blood than serum.
The ratio of THC-COOH concentration in blood to serum was calculated for the eight
paired blood and serum authentic cases to identify a correlation between the different
biological matrices. Similarly, Giroud et al. (2001) calculated the ratios of THC, 11-OHTHC, and THC-COOH concentrations in plasma or serum to whole blood for eight paired
plasma and whole blood cases and six paired postmortem blood and serum cases. Their
results were similar in that THC-COOH was detected in all the samples, followed by
THC and then 11-OH-THC. However, they concluded that these cannabinoids were
detected at higher concentrations in plasma and serum than whole blood.
Moreover, studies have concluded that cannabinoid concentrations are greater in
serum than whole blood due to high plasma protein binding and poor cannabinoid
distribution in erythrocytes (Giroud et al., 2001; Schwilke et al., 2009; Urfer et al., 2014).
The current project produced mixed results in which the ratio of THC-COOH
concentration in blood to serum ranged from 0.4-5.6. Further research with a larger
sample size is necessary to elucidate cannabinoid distribution in blood and serum. Other
important parameters that should be considered include storage temperature and the type
of collection tubes used for the hospital serum and blood samples. These factors may
influence the stability of cannabinoids in biological samples, and therefore explain the
differences in the obtained results.
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Conclusion
The cross-validation for cannabinoids in serum by GC-MS/MS was performed
based on the previous validation for cannabinoids in blood by GC-MS/MS at the NYCOCME. These methods involved SPE followed by GCTQ for the simultaneous
quantification of CBD, THC, CBN, 11-OH-THC, and THC-COOH. In addition, they
were applied to serum (n = 20) and blood (n = 16) authentic case samples obtained from
the NYC-OCME to investigate cannabinoid distribution in serum and blood. Lastly, the
present method is important for forensic cases that require a high degree of sensitivity
and selectivity for the determination of cannabinoids in serum.
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Appendix
Appendix A: Acronyms and Abbreviations
11-OH-THC

11-hydroxy-Δ9-tetrahydrocannabinol

ANOVA

Analysis of Variance

CBD

Cannabidiol

CBN

Cannabinol

CV

Coefficient of Variation

DUID

Driving Under the Influence of Drugs

EI

Electron Impact

GC

Gas Chromatography

GC-MS

Gas Chromatography Mass Spectrometry

GC-MS/MS

Gas Chromatography Tandem Mass Spectrometry

GCTQ

Gas Chromatography Coupled to Triple Quadrupole Tandem Mass
Spectrometry

LC-MS

Liquid Chromatography Mass Spectrometry

LC-MS/MS

Liquid Chromatography Tandem Mass Spectrometry

LLE

Liquid-Liquid Extraction

LOD

Limit of Detection

LOQ

Limit of Quantitation

MRM

Multiple Reaction Monitoring

MS

Mass Spectrometer

NYC-OCME

New York City Office of Chief Medical Examiner

QC

Quality Control
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S/N

Signal-to-Noise

SOP

Standard Operating Procedure

SPE

Solid Phase Extraction

SWGTOX

Scientific Working Group for Forensic Toxicology

THC

Δ9-tetrahydrocannabinol

THC-COOH

11-nor-9-carboxy-Δ9-tetrahydrocannabinol

TIC

Total Ion Chromatogram
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Appendix B: Extracted Ion Chromatograms of Target Analytes at the Low QC (3 ng/mL)
CBD

THC

CBN

35
11-OH-THC

THC-COOH
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Appendix C: Results for Blood (n = 16) and Serum (n = 20) Authentic Case Samples
Case
Number

Compound
Name

1

Concentration (ng/mL)

Source of
Blood
Tested

Blood

Serum

THC

7.7

Not Detected

11-OH-THC

3.2

Not Detected

THC-COOH

38.9

12.9

THC

Not Detected

2.5

11-OH-THC

Not Detected

1.5

THC-COOH

44.8

89.1

3

THC-COOH

> 100

28.9

Hospital
Blood

4

THC-COOH

N/A

1.9

N/A

5

THC-COOH

2.5

4.4

Hospital
Blood

6

THC-COOH

N/A

6.3

N/A

7

THC

1.8

Not Detected

11-OH-THC

1.4

Not Detected

Hospital
Blood

THC-COOH

8.8

3.2

8

THC-COOH

4.9

3.4

Hospital
Blood

9

THC-COOH

3.4

9.6

Hospital
Blood

10

THC-COOH

35.1

79.7

Hospital
Blood

11

CBD

1.2

Not Detected

Femoral

THC

4.6

Not Detected

11-OH-THC

1.8

Not Detected

THC-COOH

> 100

> 100

12

THC-COOH

N/A

8.5

N/A

13

THC-COOH

N/A

28.4

N/A

14

THC

2.3

Not Detected

11-OH-THC

2.1

Not Detected

Hospital
Blood

2

Additional
Comments

Hospital
Blood

Hospital
Blood

Suicide
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THC-COOH

47.6

32.4

15

THC-COOH

21.1

5.3

Hospital
Blood

16

THC-COOH

5.5

4.2

Hospital
Blood

17

THC-COOH

16.4

4.9

Hospital
Blood

18

THC

1.9

Not Detected

11-OH-THC

1.3

Not Detected

Hospital
Blood

THC-COOH

23.9

36.6

19

THC-COOH

8.7

6.7

Hospital
Blood

20

THC

2

Not Detected

11-OH-THC

2.2

Not Detected

Hospital
Blood

THC-COOH

54.9

9.8

